RxDoctor Payments Data

Sarwan Seth, MD

Adult Medicine · East Orange, NJNPI 1295765527

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AstraZeneca at 32.4% of the total. That places this record below the midpoint for adult medicine clinicians in NJ, where the typical reported total is $356.

$268in general payments, 2019–2025

Across 11 payments — averaging $24.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$87
  • Dexcom, Inc.$44
  • Gilead$35
  • Corcept Therapeutics$26
  • Abbott$24
  • Medtronic$23
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$268100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$268 in reported general payments places this provider in the 40th percentile of 48 adult medicine providers in New Jersey.

See all adult medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$73,008
Medicare patients
147
Services billed
819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban295$113,002
TivicayDolutegravir Sodium35$48,755
JanuviaSitagliptin Phosphate48$36,317
JardianceEmpagliflozin59$30,304
EntrestoSacubitril/Valsartan46$18,678
TradjentaLinagliptin47$17,625
TrulicityDulaglutide17$17,021
Atazanavir Sulfate12$13,910
SantylCollagenase Clostridium Hist.27$13,779
Sevelamer Carbonate33$12,198
AbrysvoRsv Vacc, Pref A And Pref B/Pf33$10,299
XareltoRivaroxaban17$9,397
Modafinil12$6,944
Atorvastatin Calcium482$6,067
Cinacalcet Hcl17$5,486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$15$47,929106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 48 adult medicine providers in New Jersey.

Other adult medicine in East Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →